{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:17:01Z","timestamp":1793891821152,"version":"4.8.0"},"reference-count":154,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,10,28]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>Immune checkpoint inhibitor (ICI) treatment has become an important therapeutic option for various cancer types. Although the treatment is effective, ICI can overstimulate the patient\u2019s immune system, leading to potentially severe immune-related adverse events (irAEs), including hepatitis, colitis, pneumonitis and myocarditis. The initial mainstay of treatments includes the administration of corticosteroids. There is little evidence how to treat steroid-resistant (sr) irAEs. It is mainly based on small case series or single case reports. This systematic review summarizes available evidence about sr-irAEs. We conducted a systematic literature search in PubMed. Additionally, we included European Society for Medical Oncology, Society for Immunotherapy of Cancer, National Comprehensive Cancer Network and American Society of Clinical Oncology Guidelines for irAEs in our assessment. The study population of all selected publications had to include patients with cancer who developed hepatitis, colitis, pneumonitis or myocarditis during or after an immunotherapy treatment and for whom corticosteroid therapy was not sufficient. Our literature search was not restricted to any specific cancer diagnosis. Case reports were also included. There is limited data regarding life-threatening sr-irAEs of colon\/liver\/lung\/heart and the majority of publications are single case reports. Most publications investigated sr colitis (n=26), followed by hepatitis (n=21), pneumonitis (n=17) and myocarditis (n=15). There is most data for mycophenolate mofetil (MMF) to treat sr hepatitis and for infliximab, followed by vedolizumab, to treat sr colitis. Regarding sr pneumonitis there is most data for MMF and intravenous immunoglobulins (IVIG) while data regarding infliximab are conflicting. In sr myocarditis, most evidence is available for the use of abatacept or anti-thymocyte globulin (ATG) (both with or without MMF) or ruxolitinib with abatacept. This review highlights the need for prompt recognition and treatment of sr hepatitis, colitis, pneumonitis and myocarditis. Guideline recommendations for sr situations are not defined precisely. Based on our search, we recommend\u2014as first line treatment\u2014(1) MMF for sr hepatitis, (2) infliximab for sr colitis, followed by vedolizumab, (3) MMF and IVIG for sr pneumonitis and (4) abatacept or ATG (both with or without MMF) or ruxolitinib with abatacept for sr myocarditis. These additional immunosuppressive agents should be initiated promptly if there is no sufficient response to corticosteroids within 3\u2009days.<\/jats:p>","DOI":"10.1136\/jitc-2023-007409","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T13:05:10Z","timestamp":1705496710000},"page":"e007409","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":75,"title":["Corticosteroid-resistant immune-related adverse events: a systematic review"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct05414552","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04438382","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03619876","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5800-6446","authenticated-orcid":false,"given":"Eveline","family":"Daetwyler","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6672-3135","authenticated-orcid":false,"given":"Till","family":"Wallrabenstein","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University Hospital Basel, Basel, Switzerland"},{"name":"Division of Hematology and Medical Oncology, University Medical Center Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3559-6855","authenticated-orcid":false,"given":"David","family":"K\u00f6nig","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C","family":"Cappelli","sequence":"additional","affiliation":[{"name":"Divison of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarushka","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Beaumont RCSI Cancer Centre, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1933-8178","authenticated-orcid":false,"given":"Alfred","family":"Zippelius","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University Hospital Basel, Basel, Switzerland"},{"name":"Department of Biomedicine, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8910-5620","authenticated-orcid":false,"given":"Heinz","family":"L\u00e4ubli","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University Hospital Basel, Basel, Switzerland"},{"name":"Department of Biomedicine, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,1,17]]},"reference":[{"key":"2025100308110668000_12.1.e007409.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001"},{"key":"2025100308110668000_12.1.e007409.2","unstructured":"SITC Immunotherapy.Pdf [Internet]. n.d. Available: http:\/\/dx.doi.org\/jitc-2021-002435"},{"key":"2025100308110668000_12.1.e007409.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"2025100308110668000_12.1.e007409.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2025100308110668000_12.1.e007409.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016"},{"key":"2025100308110668000_12.1.e007409.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"2025100308110668000_12.1.e007409.7","unstructured":"Common terminology criteria for adverse events (CTCAE). n.d. Available: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"2025100308110668000_12.1.e007409.8","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune Checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"key":"2025100308110668000_12.1.e007409.9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of cancer (SITC) consensus definitions for immune Checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025100308110668000_12.1.e007409.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2005"},{"key":"2025100308110668000_12.1.e007409.11","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune Checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"key":"2025100308110668000_12.1.e007409.12","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/COC.0000000000000374","article-title":"Hepatotoxicity after immune Checkpoint inhibitor therapy in Melanoma: natural progression and management","volume":"41","author":"Huffman","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"2025100308110668000_12.1.e007409.13","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/liv.13746","article-title":"Hepatotoxicity of immune Checkpoint inhibitors: an evolving picture of risk associated with a vital class of Immunotherapy agents","volume":"38","author":"Suzman","year":"2018","journal-title":"Liver Int"},{"key":"2025100308110668000_12.1.e007409.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0"},{"key":"2025100308110668000_12.1.e007409.15","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJMc1807505","article-title":"Adjuvant Pembrolizumab in Resected stage III Melanoma","volume":"379","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"2025100308110668000_12.1.e007409.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8448"},{"key":"2025100308110668000_12.1.e007409.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030"},{"key":"2025100308110668000_12.1.e007409.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2025100308110668000_12.1.e007409.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.1927"},{"key":"2025100308110668000_12.1.e007409.20","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2018-101146"},{"key":"2025100308110668000_12.1.e007409.21","doi-asserted-by":"crossref","unstructured":"Patrinely JR , McGuigan B , Chandra S , et al . A multicenter characterization of hepatitis associated with immune Checkpoint inhibitors. OncoImmunology 2021;10. doi:10.1080\/2162402X.2021.1875639","DOI":"10.1080\/2162402X.2021.1875639"},{"key":"2025100308110668000_12.1.e007409.22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001322","article-title":"When steroids are not enough in immune-related hepatitis: Current clinical challenges discussed on the basis of a case report","volume":"8","author":"Ziogas","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100308110668000_12.1.e007409.23","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000268","article-title":"Severe steroid-resistant anti-Pd1 T-cell Checkpoint inhibitor-induced hepatotoxicity driven by biliary injury","volume":"2","author":"Doherty","year":"2017","journal-title":"ESMO Open"},{"key":"2025100308110668000_12.1.e007409.24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1684\/ejd.2017.2973","article-title":"Azathioprine combination therapy for steroid-refractory hepatic immune system-related adverse events","volume":"27","author":"Iwamoto","year":"2017","journal-title":"Eur J Dermatol"},{"key":"2025100308110668000_12.1.e007409.25","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated hepatitis: Clinicopathologic characterization in a series of 11 cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"2025100308110668000_12.1.e007409.26","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.jtho.2021.06.024","article-title":"Beyond steroids: immunosuppressants in steroid-refractory or resistant immune-related adverse events","volume":"16","author":"Luo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025100308110668000_12.1.e007409.27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jhepr.2019.02.001","article-title":"Infliximab for the treatment of refractory immune-related hepatitis secondary to Checkpoint inhibitors: A case report","volume":"1","author":"Corrigan","year":"2019","journal-title":"JHEP Rep"},{"key":"2025100308110668000_12.1.e007409.28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2206"},{"key":"2025100308110668000_12.1.e007409.29","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-208102","article-title":"Resolution of Ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy","volume":"2015","author":"Ahmed","year":"2015","journal-title":"BMJ Case Rep"},{"key":"2025100308110668000_12.1.e007409.30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejca.2017.09.012","article-title":"\u201cCorrigendum to \"severe hepatitis under combined Immunotherapy: resolution under corticosteroids plus anti-Thymocyte Immunoglobulins\" [Eur J cancer 81 (August 2017) 203-205]\u201d","volume":"87","author":"Sp\u00e4nkuch","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025100308110668000_12.1.e007409.31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jjco\/hyw167","article-title":"Severe hepatitis arising from Ipilimumab administration, following Melanoma treatment with Nivolumab","volume":"47","author":"Tanaka","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"2025100308110668000_12.1.e007409.32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00262-017-2107-7","article-title":"Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report","volume":"67","author":"McGuire","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"2025100308110668000_12.1.e007409.33","doi-asserted-by":"crossref","DOI":"10.1093\/omcr\/omaa027","article-title":"Mycophenolate mofetil as a successful treatment of corticosteroid-resistant immune Checkpoint inhibitor-induced hepatitis","volume":"2020","author":"Nakano","year":"2020","journal-title":"Oxf Med Case Reports"},{"key":"2025100308110668000_12.1.e007409.34","doi-asserted-by":"crossref","DOI":"10.1186\/s13256-020-02541-3","article-title":"Ursodeoxycholic acid and Bezafibrate were useful for steroid-refractory, immune-related hepatitis: a case report","volume":"14","author":"Onishi","year":"2020","journal-title":"J Med Case Rep"},{"key":"2025100308110668000_12.1.e007409.35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.14309\/ajg.0000000000000398","article-title":"Clinical characteristics and adverse impact of hepatotoxicity due to immune Checkpoint inhibitors","volume":"115","author":"Miller","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2025100308110668000_12.1.e007409.36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejca.2020.02.041","article-title":"Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic Melanoma treated with immune Checkpoint inhibitors","volume":"130","author":"Romanski","year":"2020","journal-title":"Eur J Cancer"},{"key":"2025100308110668000_12.1.e007409.37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/CJI.0000000000000354","article-title":"Primary biliary cirrhosis and granulomatous hepatitis after immune Checkpoint blockade in patients with metastatic Melanoma: report of 2 cases and literature discussion","volume":"44","author":"Ruini","year":"2021","journal-title":"J Immunother"},{"key":"2025100308110668000_12.1.e007409.38","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/imj.15186","article-title":"Checkpoint inhibitor induced steroid refractory drug-induced liver injury","volume":"51","author":"Au","year":"2021","journal-title":"Intern Med J"},{"key":"2025100308110668000_12.1.e007409.39","article-title":"Mycophenolate mofetil for immune Checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review","volume":"5","author":"Ueno","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"key":"2025100308110668000_12.1.e007409.40","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of Immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2025100308110668000_12.1.e007409.41","doi-asserted-by":"crossref","unstructured":"Zhang HC , Luo W , Wang Y . Acute liver injury in the context of immune Checkpoint inhibitor-related colitis treated with Infliximab. J Immunotherapy Cancer 2019;7. doi:10.1186\/s40425-019-0532-1","DOI":"10.1186\/s40425-019-0532-1"},{"key":"2025100308110668000_12.1.e007409.42","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-88824-1","article-title":"Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease","volume":"11","author":"Hagiwara","year":"2021","journal-title":"Sci Rep"},{"key":"2025100308110668000_12.1.e007409.43","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41409-020-01122-8","article-title":"Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease","volume":"56","author":"Maas-Bauer","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"2025100308110668000_12.1.e007409.44","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.212"},{"key":"2025100308110668000_12.1.e007409.45","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.transci.2014.04.005","article-title":"Extracorporeal Photopheresis in acute and chronic graft-versus-host disease","volume":"50","author":"Greinix","year":"2014","journal-title":"Transfus Apher Sci"},{"key":"2025100308110668000_12.1.e007409.46","doi-asserted-by":"crossref","unstructured":"Prieux-Klotz C , Dior M , Damotte D , et al . Immune Checkpoint inhibitor-induced colitis. Diagnosis and Management Target Oncol 2017. doi:10.1007\/s11523-017-0495-4","DOI":"10.1007\/s11523-017-0495-4"},{"key":"2025100308110668000_12.1.e007409.47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611299"},{"key":"2025100308110668000_12.1.e007409.48","doi-asserted-by":"crossref","first-page":"405","DOI":"10.12998\/wjcc.v7.i4.405","article-title":"Immune Checkpoint inhibitor-induced colitis: A comprehensive review","volume":"7","author":"Som","year":"2019","journal-title":"World J Clin Cases"},{"key":"2025100308110668000_12.1.e007409.49","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/OP.20.00002","article-title":"Immune Checkpoint inhibitor-mediated diarrhea and colitis: A clinical review","volume":"16","author":"Gong","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2025100308110668000_12.1.e007409.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"2025100308110668000_12.1.e007409.51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"2025100308110668000_12.1.e007409.52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6750"},{"key":"2025100308110668000_12.1.e007409.53","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000278","article-title":"Immune Checkpoint inhibition-related colitis: symptoms, endoscopic features, Histology and response to management","volume":"3","author":"Geukes Foppen","year":"2018","journal-title":"ESMO Open"},{"key":"2025100308110668000_12.1.e007409.54","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000507579","article-title":"Retrospective analysis of treatment and complications of immune Checkpoint inhibitor-associated colitis: histological ulcerations as potential Predictor for a steroid-refractory disease course","volume":"5","author":"Burla","year":"2020","journal-title":"Inflamm Intest Dis"},{"key":"2025100308110668000_12.1.e007409.55","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy104"},{"key":"2025100308110668000_12.1.e007409.56","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3748\/wjg.v23.i11.2023","article-title":"Colonic ulcerations may predict steroid-refractory course in patients with Ipilimumab-mediated Enterocolitis","volume":"23","author":"Jain","year":"2017","journal-title":"WJG"},{"key":"2025100308110668000_12.1.e007409.57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198712243172603"},{"key":"2025100308110668000_12.1.e007409.58","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000451","article-title":"Mucosal inflammation predicts response to systemic steroids in immune Checkpoint inhibitor colitis","volume":"8","author":"Mooradian","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100308110668000_12.1.e007409.59","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e32835fb524"},{"key":"2025100308110668000_12.1.e007409.60","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-216641","article-title":"Vedolizumab: a novel treatment for Ipilimumab-induced colitis","volume":"2016","author":"Hsieh","year":"2016","journal-title":"BMJ Case Rep"},{"key":"2025100308110668000_12.1.e007409.61","doi-asserted-by":"crossref","first-page":"360","DOI":"10.12659\/AJCR.908570","article-title":"Resolution of Infliximab-refractory Nivolumab-induced acute severe Enterocolitis after cyclosporine treatment in a patient with non-small cell lung cancer","volume":"19","author":"Iyoda","year":"2018","journal-title":"Am J Case Rep"},{"key":"2025100308110668000_12.1.e007409.62","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1056\/NEJMc2002527","article-title":"Tofacitinib for refractory immune-related colitis from PD-1 therapy","volume":"382","author":"Esfahani","year":"2020","journal-title":"N Engl J Med"},{"key":"2025100308110668000_12.1.e007409.63","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12888"},{"key":"2025100308110668000_12.1.e007409.64","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4292\/wjgpt.v10.i1.29","article-title":"Ipilimumab and Nivolumab induced steroid-refractory colitis treated with Infliximab: A case report","volume":"10","author":"Nassri","year":"2019","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"2025100308110668000_12.1.e007409.65","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/imj.14854","article-title":"Impending Infliximab access crisis: a case of steroid-refractory, relapsing Immunotherapy-induced colitis responsive to Infliximab","volume":"50","author":"Connolly","year":"2020","journal-title":"Intern Med J"},{"key":"2025100308110668000_12.1.e007409.66","doi-asserted-by":"crossref","first-page":"101604","DOI":"10.1016\/j.clinre.2020.101604","article-title":"Vedolizumab for steroid & Infliximab refractory immune Checkpoint inhibitor associated colitis","volume":"45","author":"Klemm","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2025100308110668000_12.1.e007409.67","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000000946","article-title":"Refractory Checkpoint inhibitor colitis responsive to Ustekinumab","volume":"9","author":"Perez Del Nogal","year":"2022","journal-title":"ACG Case Rep J"},{"key":"2025100308110668000_12.1.e007409.68","first-page":"1124","article-title":"Management of persistent colitis after successful Immunotherapy for non-small cell carcinoma of the lung","volume":"60","author":"Zellweger","year":"2022","journal-title":"Z Gastroenterol"},{"key":"2025100308110668000_12.1.e007409.69","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1056\/NEJMc1912274","article-title":"Extracorporeal Photopheresis for colitis induced by Checkpoint-inhibitor therapy","volume":"382","author":"Apostolova","year":"2020","journal-title":"N Engl J Med"},{"key":"2025100308110668000_12.1.e007409.70","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.06.025"},{"key":"2025100308110668000_12.1.e007409.71","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.12.028"},{"key":"2025100308110668000_12.1.e007409.72","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-008-0641-z"},{"key":"2025100308110668000_12.1.e007409.73","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","article-title":"Cancer Immunotherapy with anti-CTLA-4 Monoclonal antibodies induces an inflammatory bowel disease","volume":"10","author":"Marthey","year":"2016","journal-title":"ECCOJC"},{"key":"2025100308110668000_12.1.e007409.74","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5716"},{"key":"2025100308110668000_12.1.e007409.75","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-1962-6"},{"key":"2025100308110668000_12.1.e007409.76","doi-asserted-by":"crossref","unstructured":"Abu-Sbeih H , Ali FS , Wang Y . Clinical review on the utility of fecal microbiota transplantation in immunocompromised patients. Curr Gastroenterol Rep 2019;21. doi:10.1007\/s11894-019-0677-6","DOI":"10.1007\/s11894-019-0677-6"},{"key":"2025100308110668000_12.1.e007409.77","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0461-4","article-title":"Outcomes of Vedolizumab therapy in patients with immune Checkpoint inhibitor-induced colitis: a multi-center study","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2025100308110668000_12.1.e007409.78","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-009-0839-8"},{"key":"2025100308110668000_12.1.e007409.79","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/jgh3.12531","article-title":"Calcineurin inhibitors in steroid and anti-TNF-alpha refractory immune Checkpoint inhibitor colitis","volume":"5","author":"Zhang","year":"2021","journal-title":"JGH Open"},{"key":"2025100308110668000_12.1.e007409.80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2031717"},{"key":"2025100308110668000_12.1.e007409.81","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0238-9"},{"key":"2025100308110668000_12.1.e007409.82","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/apt.17250","article-title":"Safety and efficacy of Infliximab and corticosteroid therapy in Checkpoint inhibitor-induced colitis","volume":"57","author":"Dahl","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2025100308110668000_12.1.e007409.83","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.10.029"},{"key":"2025100308110668000_12.1.e007409.84","doi-asserted-by":"crossref","unstructured":"Abu-Sbeih H , Ali FS , Wang X , et al . Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune Checkpoint inhibitor-induced colitis. J Immunotherapy Cancer 2019;7. doi:10.1186\/s40425-019-0577-1","DOI":"10.1186\/s40425-019-0577-1"},{"key":"2025100308110668000_12.1.e007409.85","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0711-0","article-title":"Concurrent therapy with immune Checkpoint inhibitors and TNF\u03b1 blockade in patients with gastrointestinal immune-related adverse events","volume":"7","author":"Badran","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025100308110668000_12.1.e007409.86","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.2643","article-title":"Outcomes of immune Checkpoint inhibitor-mediated colitis: multicenter cohort study","volume":"39","author":"Abu-Sbeih","year":"2021","journal-title":"JCO"},{"key":"2025100308110668000_12.1.e007409.87","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.768957","article-title":"Mechanisms of immune Checkpoint inhibitor-mediated colitis","volume":"12","author":"Westdorp","year":"2021","journal-title":"Front Immunol"},{"key":"2025100308110668000_12.1.e007409.88","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.001"},{"key":"2025100308110668000_12.1.e007409.89","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12072452","article-title":"Recent advances in the optimization of anti-TNF treatment in patients with inflammatory bowel disease","volume":"12","author":"Orfanoudaki","year":"2023","journal-title":"J Clin Med"},{"key":"2025100308110668000_12.1.e007409.90","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/581631","article-title":"Clinical use and mechanisms of Infliximab treatment on inflammatory bowel disease: a recent update","volume":"2013","author":"Guo","year":"2013","journal-title":"Biomed Res Int"},{"key":"2025100308110668000_12.1.e007409.91","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/s41409-018-0364-5","article-title":"Anti-\u03914\u03927 integrin Monoclonal antibody (Vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease","volume":"54","author":"Danylesko","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"2025100308110668000_12.1.e007409.92","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw092"},{"key":"2025100308110668000_12.1.e007409.93","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/14787210.2020.1752192","article-title":"Fecal Microbiota transplantation for treatment of patients with recurrent Clostridioides difficile infection","volume":"18","author":"Voth","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025100308110668000_12.1.e007409.94","doi-asserted-by":"publisher","DOI":"10.5946\/ce.2015.117"},{"key":"2025100308110668000_12.1.e007409.95","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu135"},{"key":"2025100308110668000_12.1.e007409.96","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir632"},{"key":"2025100308110668000_12.1.e007409.97","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1205037","article-title":"Duodenal infusion of Feces for recurrent Clostridium difficile","volume":"368","author":"van Nood","year":"2013","journal-title":"N Engl J Med"},{"key":"2025100308110668000_12.1.e007409.98","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(89)91183-5","article-title":"Treatment of ulcerative colitis by implantation of normal Colonic Flora","volume":"1","author":"Bennet","year":"1989","journal-title":"Lancet"},{"key":"2025100308110668000_12.1.e007409.99","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.08.006"},{"key":"2025100308110668000_12.1.e007409.100","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.001"},{"key":"2025100308110668000_12.1.e007409.101","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.03.045"},{"key":"2025100308110668000_12.1.e007409.102","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2019.05.002"},{"key":"2025100308110668000_12.1.e007409.103","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cncr.31043","article-title":"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature","volume":"124","author":"Pillai","year":"2018","journal-title":"Cancer"},{"key":"2025100308110668000_12.1.e007409.104","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004670","article-title":"Real-world incidence and impact of Pneumonitis in patients with lung cancer treated with immune Checkpoint inhibitors: a multi-institutional cohort study","volume":"10","author":"Tiu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100308110668000_12.1.e007409.105","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-Checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur Respir J"},{"key":"2025100308110668000_12.1.e007409.106","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001731","article-title":"Steroid-refractory PD-(L)1 Pneumonitis: incidence, clinical features, treatment, and outcomes","volume":"9","author":"Balaji","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100308110668000_12.1.e007409.107","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related Pneumonitis in patients with advanced cancer: A systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025100308110668000_12.1.e007409.108","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0352"},{"key":"2025100308110668000_12.1.e007409.109","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000840","article-title":"Chronic immune Checkpoint inhibitor Pneumonitis","volume":"8","author":"Naidoo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100308110668000_12.1.e007409.110","doi-asserted-by":"crossref","first-page":"100969","DOI":"10.1016\/j.resmer.2022.100969","article-title":"Prevalence and outcome of steroid-resistant\/refractory Pneumonitis induced by immune Checkpoint inhibitors","volume":"82","author":"Camard","year":"2022","journal-title":"Respiratory Medicine and Research"},{"key":"2025100308110668000_12.1.e007409.111","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001884","article-title":"Success and failure of additional immune Modulators in steroid-refractory\/resistant Pneumonitis related to immune Checkpoint blockade","volume":"9","author":"Beattie","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100308110668000_12.1.e007409.112","article-title":"Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: case report and review of the literature","volume":"27","author":"Petri","year":"2019","journal-title":"Respir Med Case Rep"},{"key":"2025100308110668000_12.1.e007409.113","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217745144"},{"key":"2025100308110668000_12.1.e007409.114","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/qjmed\/hcz224","article-title":"Early Infliximab in life-threatening immune-mediated Pneumonitis","volume":"112","author":"Cooksley","year":"2019","journal-title":"QJM"},{"key":"2025100308110668000_12.1.e007409.115","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5582\/ddt.2019.01032","article-title":"Rapid temporal improvement of Pembrolizumab-induced Pneumonitis using the anti-TNF-\u0391 antibody Infliximab","volume":"13","author":"Sawai","year":"2019","journal-title":"Drug Discov Ther"},{"key":"2025100308110668000_12.1.e007409.116","doi-asserted-by":"crossref","unstructured":"Andruska N , Mahapatra L , Hebbard C , et al . Severe Pneumonitis refractory to steroids following anti-PD-1 Immunotherapy. BMJ Case Rep 2018:bcr2018225937. doi:10.1136\/bcr-2018-225937","DOI":"10.1136\/bcr-2018-225937"},{"key":"2025100308110668000_12.1.e007409.117","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.21037\/tcr-22-1162","article-title":"Infliximab in the treatment of Tislelizumab-induced steroid-refractory immune Checkpoint inhibitor-related pneumonia: case report and literature review","volume":"11","author":"Chen","year":"2022","journal-title":"Transl Cancer Res"},{"key":"2025100308110668000_12.1.e007409.118","article-title":"Rapid improvement following receipt of Infliximab in steroid-refractory Durvalumab-associated grade 3 Pneumonitis","volume":"14","author":"Huang","year":"2022","journal-title":"Cureus"},{"key":"2025100308110668000_12.1.e007409.119","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0400-4","article-title":"Treatment of mycophenolate-resistant immune-related organizing pneumonia with Infliximab","volume":"6","author":"Ortega Sanchez","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2025100308110668000_12.1.e007409.120","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00262-020-02600-0","article-title":"Successful treatment of steroid-refractory immune Checkpoint inhibitor-related Pneumonitis with triple combination therapy: a case report","volume":"69","author":"Utsumi","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"2025100308110668000_12.1.e007409.121","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.673877","article-title":"Case report: Nintedanib for Pembrolizumab-related Pneumonitis in a patient with non-small cell lung cancer","volume":"11","author":"Xie","year":"2021","journal-title":"Front Oncol"},{"key":"2025100308110668000_12.1.e007409.122","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1386362","article-title":"The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with Checkpoint inhibitors","volume":"7","author":"L\u00e4ubli","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100308110668000_12.1.e007409.123","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9101484","article-title":"Insights into potential pathogenesis and treatment options for immune-Checkpoint inhibitor-related Pneumonitis","volume":"9","author":"Ando","year":"2021","journal-title":"Biomedicines"},{"key":"2025100308110668000_12.1.e007409.124","doi-asserted-by":"publisher","DOI":"10.1172\/jci128654"},{"key":"2025100308110668000_12.1.e007409.125","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1908079116"},{"key":"2025100308110668000_12.1.e007409.126","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037"},{"key":"2025100308110668000_12.1.e007409.127","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30608-9"},{"key":"2025100308110668000_12.1.e007409.128","doi-asserted-by":"crossref","unstructured":"Moslehi JJ , Salem J-E , Sosman JA , et al . Increased reporting of fatal immune Checkpoint inhibitor-associated myocarditis. Lancet 2018;391. doi:10.1016\/S0140-6736(18)30533-6","DOI":"10.1016\/S0140-6736(18)30533-6"},{"key":"2025100308110668000_12.1.e007409.129","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034497"},{"key":"2025100308110668000_12.1.e007409.130","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab674"},{"key":"2025100308110668000_12.1.e007409.131","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214"},{"key":"2025100308110668000_12.1.e007409.132","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","article-title":"ESC guidelines on Cardio-oncology developed in collaboration with the European hematology Association (EHA), the European society for therapeutic Radiology and oncology (ESTRO) and the International Cardio-oncology society (IC-OS)","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2025100308110668000_12.1.e007409.133","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001887","article-title":"Intensified immunosuppressive therapy in patients with immune Checkpoint inhibitor-induced myocarditis","volume":"8","author":"Cautela","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100308110668000_12.1.e007409.134","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1901677"},{"key":"2025100308110668000_12.1.e007409.135","doi-asserted-by":"crossref","unstructured":"Jespersen MS , Fan\u00f8 S , Sten\u00f8r C , et al . A case report of immune Checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like Myositis treated with Abatacept and mycophenolate mofetil. European Heart Journal - Case Reports 2021;5. doi:10.1093\/ehjcr\/ytab342","DOI":"10.1093\/ehjcr\/ytab342"},{"key":"2025100308110668000_12.1.e007409.136","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1111\/imj.15566","article-title":"Use of Abatacept in steroid refractory, immune Checkpoint-induced myocarditis","volume":"51","author":"Kalapurackal Mathai","year":"2021","journal-title":"Intern Med J"},{"key":"2025100308110668000_12.1.e007409.137","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1903064"},{"key":"2025100308110668000_12.1.e007409.138","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3747\/co.26.4381","article-title":"Fatal myocarditis and Rhabdomyositis in a patient with stage IV Melanoma treated with combined Ipilimumab and Nivolumab","volume":"26","author":"Saibil","year":"2019","journal-title":"Current Oncology"},{"key":"2025100308110668000_12.1.e007409.139","doi-asserted-by":"crossref","first-page":"683","DOI":"10.7326\/L17-0396","article-title":"Survival after fulminant myocarditis induced by immune-Checkpoint inhibitors","volume":"167","author":"Arangalage","year":"2017","journal-title":"Ann Intern Med"},{"key":"2025100308110668000_12.1.e007409.140","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/jca.21890","article-title":"Immune Checkpoint inhibitor toxicity: A new indication for therapeutic plasma exchange","volume":"36","author":"Compton","year":"2021","journal-title":"J of Clinical Apheresis"},{"key":"2025100308110668000_12.1.e007409.141","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.21037\/tlcr-20-1095","article-title":"Pembrolizumab-induced myocarditis in a patient with malignant Mesothelioma: plasma exchange as a successful emerging therapy-case report","volume":"10","author":"Schiopu","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"2025100308110668000_12.1.e007409.142","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.253"},{"key":"2025100308110668000_12.1.e007409.143","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/CJI.0000000000000239","article-title":"Autoimmune myocarditis caused by immune Checkpoint inhibitors treated with Antithymocyte globulin","volume":"41","author":"Jain","year":"2018","journal-title":"J Immunother"},{"key":"2025100308110668000_12.1.e007409.144","first-page":"1","article-title":"Steroid-refractory autoimmune myocarditis after Pembrolizumab therapy: failure of equine anti-Thymocyte globulin to prevent heart failure","volume":"2","author":"Baclig","year":"2019","journal-title":"J Clin Case Rep"},{"key":"2025100308110668000_12.1.e007409.145","doi-asserted-by":"crossref","first-page":"944013","DOI":"10.3389\/fimmu.2022.944013","article-title":"Case report: treatment for steroid-refractory immune-related myocarditis with tofacitinib","volume":"13","author":"Xing","year":"2022","journal-title":"Front Immunol"},{"key":"2025100308110668000_12.1.e007409.146","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.05.005"},{"key":"2025100308110668000_12.1.e007409.147","article-title":"Treatment of corticosteroid refractory immune Checkpoint inhibitor myocarditis with Infliximab: a case series","volume":"7","author":"Zhang","year":"2021","journal-title":"Cardiooncology"},{"key":"2025100308110668000_12.1.e007409.148","doi-asserted-by":"crossref","first-page":"770631","DOI":"10.3389\/fphar.2021.770631","article-title":"Case series of steroid-resistant immune Checkpoint inhibitor associated myocarditis: A comparative analysis of corticosteroid and tofacitinib treatment","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025100308110668000_12.1.e007409.149","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/Ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-Checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"key":"2025100308110668000_12.1.e007409.150","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4083"},{"key":"2025100308110668000_12.1.e007409.151","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-484642"},{"key":"2025100308110668000_12.1.e007409.152","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000761"},{"key":"2025100308110668000_12.1.e007409.153","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216109"},{"key":"2025100308110668000_12.1.e007409.154","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/ard-2023-223885","article-title":"Comparative safety and effectiveness of TNF inhibitors, Il6 inhibitors and methotrexate for the treatment of immune Checkpoint inhibitor-associated arthritis","volume":"82","author":"Bass","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-007409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T15:11:25Z","timestamp":1759504285000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-007409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":154,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,17]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/jitc-2023-007409"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-007409","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}